ERIS LIFESCIENCES
|
ERIS LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 44.73 | 25.83 | 28.83 | 28.10 | 29.88 |
| CEPS(Rs) | 66.93 | 50.67 | 42.62 | 36.12 | 34.61 |
| DPS(Rs) | - | 7.35 | - | 7.35 | 6.01 |
| Book NAV/Share(Rs) | 280.75 | 208.83 | 189.79 | 161.28 | 140.25 |
| Tax Rate(%) | -1.40 | 23.36 | 7.93 | 7.53 | 8.23 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 34.09 | 34.22 | 31.91 | 30.41 | 34.77 |
| EBIT Margin(%) | 25.54 | 24.22 | 24.41 | 24.41 | 32.00 |
| Pre Tax Margin(%) | 19.62 | 16.44 | 20.40 | 22.92 | 31.70 |
| PAT Margin (%) | 19.90 | 12.60 | 18.78 | 21.20 | 29.09 |
| Cash Profit Margin (%) | 28.49 | 23.21 | 27.41 | 27.83 | 33.73 |
| Performance Ratios | |||||
| ROA(%) | 9.18 | 5.48 | 7.72 | 13.40 | 21.27 |
| ROE(%) | 19.23 | 13.81 | 16.64 | 18.25 | 23.33 |
| ROCE(%) | 14.47 | 13.59 | 12.37 | 17.30 | 25.29 |
| Asset Turnover(x) | 0.46 | 0.43 | 0.41 | 0.63 | 0.73 |
| Sales/Fixed Asset(x) | 0.53 | 0.55 | 0.56 | 0.90 | 1.33 |
| Working Capital/Sales(x) | -6.06 | -18.77 | -9.19 | 5.49 | 3.26 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.88 | 1.82 | 1.80 | 1.11 | 0.75 |
| Receivable days | 63.88 | 54.06 | 61.68 | 46.91 | 39.44 |
| Inventory Days | 43.27 | 32.16 | 27.66 | 25.78 | 27.78 |
| Payable days | 151.85 | 140.91 | 165.04 | 125.63 | 155.58 |
| Valuation Parameters | |||||
| PER(x) | 29.02 | 54.83 | 29.18 | 20.36 | 23.06 |
| PCE(x) | 19.40 | 27.96 | 19.74 | 15.84 | 19.91 |
| Price/Book(x) | 4.62 | 6.78 | 4.43 | 3.55 | 4.91 |
| Yield(%) | - | 0.52 | - | 1.28 | 0.87 |
| EV/Net Sales(x) | 6.46 | 7.43 | 6.36 | 5.07 | 6.95 |
| EV/Core EBITDA(x) | 17.93 | 20.75 | 18.29 | 15.61 | 18.31 |
| EV/EBIT(x) | 24.33 | 29.84 | 24.75 | 19.85 | 20.97 |
| EV/CE(x) | 3.26 | 4.07 | 2.40 | 2.83 | 4.43 |
| M Cap / Sales | 5.75 | 6.67 | 5.69 | 4.62 | 6.95 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.15 | 44.02 | 19.23 | 25.10 | 11.15 |
| Core EBITDA Growth(%) | 8.91 | 48.22 | 27.51 | 7.20 | 16.31 |
| EBIT Growth(%) | 15.42 | 39.53 | 19.81 | -3.50 | 12.60 |
| PAT Growth(%) | 72.82 | -5.65 | 6.14 | -7.79 | 14.26 |
| EPS Growth(%) | 73.16 | -10.39 | 2.58 | -5.94 | 14.23 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.59 | 0.85 | 1.06 | 0.38 | 0.02 |
| Current Ratio(x) | 0.76 | 0.89 | 0.91 | 1.62 | 2.51 |
| Quick Ratio(x) | 0.56 | 0.67 | 0.84 | 1.41 | 2.16 |
| Interest Cover(x) | 4.31 | 3.11 | 6.09 | 16.46 | 105.81 |
| Total Debt/Mcap(x) | 0.13 | 0.13 | 0.24 | 0.11 | - |
Compare Financial Ratios of peers of ERIS LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ERIS LIFESCIENCES | ₹17,701.6 Cr | 3.6% | 10% | -20.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹452,707.0 Cr | 3.9% | 7.8% | 13% | Stock Analytics | |
| DIVIS LABORATORIES | ₹303,962.0 Cr | 11.5% | 20.6% | 68% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹179,494.0 Cr | 1% | 1.8% | 34.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹115,769.0 Cr | 1.1% | 11.8% | 14.9% | Stock Analytics | |
| CIPLA | ₹113,912.0 Cr | 1.1% | 7.9% | -6.3% | Stock Analytics | |
ERIS LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ERIS LIFESCIENCES | 3.6% |
10% |
-20.3% |
| SENSEX | 3.3% |
13.9% |
-1.7% |
You may also like the below Video Courses
